Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies

 

 Buy Article Permissions and Reprints

ABSTRACT

Treatment of patients with nonalcoholic fatty liver has typically been focused on the management of associated conditions such as obesity, diabetes mellitus, and hyperlipidemia as well as discontinuation of potentially hepatotoxic drugs. Nonalcoholic fatty liver associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate metabolic control for patients with diabetes mellitus or hyperlipidemia is always recommended but not always effective in reversing nonalcoholic fatty liver. Promising results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, and α-tocopherol suggest that these medications may be of potential benefit in the treatment of patients with nonalcoholic fatty liver. These medications, however, need first to be tested in well-controlled trials with clinically relevant end points and extended follow-up. A better understanding of the pathogenesis and natural history of this condition will help to identify the subset of patients with nonalcoholic fatty liver at risk of progressing to advanced liver disease and, hence, the subgroup of patients who should derive the most benefit from medical therapy. In this article, we review (1) the existing medical therapy for patients with nonalcoholic fatty liver, (2) the emerging data from clinical trials evaluating potentially useful medications, and (3) the potential therapeutic implications of recent studies on the pathogenesis of this liver disease.

REFERENCES

• 1 Ludwig J, Viggiano R T, McGill D B. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease.  Mayo Clin Proc . 1980;  55 342-348
  PubMedGoogle Scholar
• 2 Matteoni C A, Younossi Z M, Gramlich T L. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology . 1999;  116 1413-1419
  CrossrefPubMedGoogle Scholar
• 3 Powell E E, Cooksley W G, Hanson R. The natural history of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years.  Hepatology . 1990;  11 74-80
  CrossrefPubMedGoogle Scholar
• 4 Teli M, Oliver F W, Burt A D. The natural history of nonalcoholic fatty liver: a follow up study.  Hepatology . 1995;  22 1714-1717
  CrossrefPubMedGoogle Scholar
• 5 Brunt E M, Janney C G, DiBisceglie A M. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol . 1999;  94 2467-2474
  CrossrefPubMedGoogle Scholar
• 6 Diehl A M, Goodman Z, Ishak K G. Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury.  Gastroenterology . 1989;  95 1056-1060
  PubMedGoogle Scholar
• 7 Lee R G. Nonalcoholic steatohepatitis. A study of 49 patients.  Hum Pathol . 1989;  20 594-599
  CrossrefPubMedGoogle Scholar
• 8 Laurin J, Lindor K D, Crippin J S. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study.  Hepatology . 1996;  23 1464-1467
  CrossrefPubMedGoogle Scholar
• 9 Angulo P, Keach J C, Batts K P. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology . 1999;  30 1356-1362
  CrossrefPubMedGoogle Scholar
• 10 Eriksson S, Eriksson K F, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition.  Acta Med Scand . 1986;  220 83-88
  PubMedGoogle Scholar
• 11 Rozental P, Biava C, Spencer H. Liver morphology and function tests in obesity and during total starvation.  Am J Dig Dis . 1967;  12 198-208
  PubMedGoogle Scholar
• 12 Drenick E J, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass.  N Engl J Med . 1970;  282 829-834
  CrossrefPubMedGoogle Scholar
• 13 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients.  Gastroenterology . 1990;  99 1408-1413
  PubMedGoogle Scholar
• 14 Andersen T, Gluud C, Franzmann M B. Hepatic effects of dietary weight loss in morbidly obese patients.  J Hepatol . 1991;  12 224-229
  CrossrefPubMedGoogle Scholar
• 15 Ueno T, Sugawara H, Sujaku K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.  J Hepatol . 1997;  27 103-107
  CrossrefPubMedGoogle Scholar
• 16 Vajro P, Fontanella A, Perna C. Persistent hyperaminotransferasemia resolving after weight reduction in obese children.  J Pediatr . 1994;  125 239-241
  PubMedGoogle Scholar
• 17 Franzese A, Vajro P, Argenziano A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.  Dig Dis Sci . 1997;  42 1428-1432
  CrossrefPubMedGoogle Scholar
• 18 Rashid M, Roberts E. Nonalcoholic steatohepatitis in children.  Journal of Pediatric Gastroenterology and Nutrition . 2000;  30 48-53
  CrossrefPubMedGoogle Scholar
• 19 Kanders B S, Blackburn G L. Very-low-calorie diets for the treatment of obesity. In: Blackburn GL, Kanders BS (eds) Obesity: Pathophysiology, Psychology and Treatment. New York: Chapman & Hall 1994: 197-215
  Google Scholar
• 20 Kolanowski J. A risk-benefit assessment of anti-obesity drugs.  Drug Saf . 1999;  20 119-131
  PubMedGoogle Scholar
• 21 Abenhaim L, Moride Y, Brenot F. Appetite-suppressant drugs and the risk of primary pulmonary hypertension.  N Engl J Med . 1996;  335 609-616
  CrossrefPubMedGoogle Scholar
• 22 Lin H Z, Yang S Q, Chuckaree C. Metformin reverses fatty liver disease in obese, leptin-deficient mice.  Nat Med . 2000;  6 998-1003
  PubMedGoogle Scholar
• 23 DeWind L T, Payne J H. Intestinal bypass surgery for morbid obesity. Long term results.  JAMA . 1976;  236 2298-2301
  CrossrefPubMedGoogle Scholar
• 24 Campbell J M, Hung T K, Karam J H. Jejunoileal bypass as a treatment of morbid obesity.  Arch Intern Med . 1977;  137 602-610
  CrossrefPubMedGoogle Scholar
• 25 Ackerman N B. Protein supplementation in the management of degenerating liver function after jejunoileal bypass.  Surg Gynecol Obstet . 1979;  149 8-14
  PubMedGoogle Scholar
• 26 Drenick E J, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition.  Gastroenterology . 1982;  82 535-548
  CrossrefPubMedGoogle Scholar
• 27 Buchman A L, Dubin M, Jenden D. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats.  Gastroenterology . 1992;  102 1363-1370
  CrossrefPubMedGoogle Scholar
• 28 Buchman A L, Dubin M D, Moukarzel A A. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation.  Hepatology . 1995;  22 1390-1403
  PubMedGoogle Scholar
• 29 Pappo I, Becovier H, Berry E m. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat.  J Clin Res . 1991;  51 106-112
  PubMedGoogle Scholar
• 30 Freud H R, Muggia-Sullan M, LaFrance R. A possible beneficial effect of metronidazole in reducing TPN- associated liver function derangements.  J Surg Res . 1985;  38 356-363
  CrossrefPubMedGoogle Scholar
• 31 Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis.  J Hepatol . 1999;  31 384
  PubMedGoogle Scholar
• 32 Guma G, Viola L, Thome M. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial (Abstract).  Hepatology . 1997;  26 387A
  PubMedGoogle Scholar
• 33 Ceriani R, Bunati S, Morini L. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis (Abstract).  Hepatology . 1998;  28 386A
  PubMedGoogle Scholar
• 34 Barak A J, Beckenhauer H C, Junnila M. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration.  Alcohol Clin Exp Res . 1993;  17 552-555
  CrossrefPubMedGoogle Scholar
• 35 Abdelmalek M, Angulo P, Jorgensen R A. Betaine for patients with nonalcoholic steatohepatitis: a promising new agent.  Gastroenterology . 2000;  118 A973
  PubMedGoogle Scholar
• 36 Gulbahar O, Karasu Z A, Ersoz G. Treatment of non- alcoholic steatohepatitis with N-acetylcysteine (Abstract).  Gastroenterology . 2000;  118 A1444
  PubMedGoogle Scholar
• 37 Hasegawa T, Yoneda M, Nakamura K. Long- and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression (Abstract).  Hepatology . 1997;  26 250A
  PubMedGoogle Scholar
• 38 Lavine J E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.  J Pediatrics . 2000;  136 734-738
  PubMedGoogle Scholar
• 39 Letterson P, Fromenty B, Terris B. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice.  J Hepatol . 1996;  24 200-208
  CrossrefPubMedGoogle Scholar
• 40 Jaeschke H, Wang Y, Essani N A. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation (Abstract).  Hepatology . 1996;  24 238A
  PubMedGoogle Scholar
• 41 Acosta D, Wenzel D G. Injury produce by free fatty acids to lysosomes and mitochondria in cultures heart muscle and endothelial cells.  Atherosclerosis . 1974;  20 417-426
  PubMedGoogle Scholar
• 42 Weltman M D, Farrell G C, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.  Gastroenterology . 1996;  111 1645-1653
  PubMedGoogle Scholar
• 43 Schuppan D, Jia J D, Brinkhaus B. Herbal products for liver diseases. A therapeutic challenge for the new millennium.  Hepatology . 1999;  30 1099-1104
  CrossrefPubMedGoogle Scholar
• 44 Yang S Q, Lin H Z, Lane M D. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.  Proc Natl Acad Sci U S A . 1997;  94 2557-2562
  CrossrefPubMedGoogle Scholar
• 45 Chavin K, Yang S Q, Lin H Z. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion.  J Biol Chem . 1999;  274 5692-5700
  PubMedGoogle Scholar
• 46 Cortez-Pinto H, Chatham J, Chacko V P. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study.  JAMA . 1999;  282 1659-1664
  CrossrefPubMedGoogle Scholar
• 47 Weltman M D, Farrel G C, Hall P. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.  Hepatology . 1998;  27 128-133
  CrossrefPubMedGoogle Scholar
• 48 George D K, Goldwurm S, MacDonald G A. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology . 1998;  114 311-318
  CrossrefPubMedGoogle Scholar
• 49 Boncovsky H L, Jawaid Q, Tortorelli K. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.  J Hepatol . 1999;  31 421-429
  CrossrefPubMedGoogle Scholar
• 50 Younossi Z M, Gramlich T, Bacon B R. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology . 1999;  30 847-850
  CrossrefPubMedGoogle Scholar
• 51 Desai T K. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis (Abstract).  Gastroenterology . 2000;  118 A975
  PubMedGoogle Scholar
• 52 Nitecki J, Jackson F W, Allen M L. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) (Abstract).  Gastroenterology . 2000;  118 A1474
  PubMedGoogle Scholar
• 53 Bonora E, Kiechi S, Willeit J. Prevalence of insulin resistance in metabolic disorders.  Diabetes . 1998;  47 1643-1649
  CrossrefPubMedGoogle Scholar
• 54 Mendler M H, Turlin B, Moirand R. Insulin resistance- associated hepatic iron overload.  Gastroenterology . 1999;  117 1155-1163
  CrossrefPubMedGoogle Scholar
• 55 Battle E H, Hespenheiden E E, Caldwell S H. Pilot study of troglitazone (Rezulin) for nonalcoholic steatohepatitis (Abstract).  Hepatology . 1998;  28 304A
  PubMedGoogle Scholar
• 56 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone.  N Engl J Med . 1998;  338 908-909
  PubMedGoogle Scholar